Chronic Hepatitis B: Treatment of chronic hepatitis B when used as monotherapy or combination therapy with interferon in patients ≥18 years with compensated liver disease and hepatitis B virus (HBV) replication (serum HBV DNA positive).
Studies in patients who have been serum hepatitis B surface antigen (HBsAg) positive for at least 6 months with elevated serum alanine aminotransferase (ALT) demonstrate that treatment with Zadaxin therapy can produce virological remission (loss of serum HBV DNA) and normalization of serum aminotransferases. Zadaxin therapy resulted in the loss of serum HBsAg in some responding patients.
Vaccine Adjuvant: As an adjuvant for influenza vaccination in immunocompromised patients. Zadaxin was studied in various dosing regimens as an adjuvant for influenza vaccine in elderly patients as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from various immunization.